Navigation Links
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Date:9/14/2009

R compared to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)**, and a 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)**.

In March 2009 at the American College of Cardiology annual meeting, Abbott presented long-term data from the SPIRIT II clinical trial of 300 patients, which showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. XIENCE V demonstrated a 57 percent reduction in the risk of MACE compared to TAXUS at three years (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)**.

In addition, there was no occurrence of stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)** in the SPIRIT II trial. The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

In May 2009 at EuroPCR, Abbott presented one-year data from the SPIRIT V (five) international, single-arm study, which evaluated XIENCE V in 2,663 patients - including more than 60 patients enrolled at two sites in China. XIENCE V demonstrated low rates of repeat procedure (target lesion revascularization or TLR), stent thrombosis and MACE in a diverse, "real world" population of patients and lesion types, including patients with diabetes, patients with multi-vessel disease and patients with highly complex lesions. In the SPIRIT V study, XIENCE V demonstrated a very low 1.8 percent rate of TLR, a 0.7 percent rate of definite/probable stent thrombosis and a 5.1 percent rate
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
2. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
3. Abbott HIV Test Demonstrates Earlier Disease Detection
4. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Abbott Named One of the Top 10 Companies for Scientists
7. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
8. Abbott to Present at Barclays Global Healthcare Conference
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Abbott Announces 11 Percent Increase in Quarterly Dividend
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Recently, academic debate has been swirling around the existence ... of phenomena, including photosynthesis, the process by which organisms ... suggested that entanglement (the quantum interconnection of two or ... separated in physical space) could be occurring in the ...
... Aug. 6 Rashid Chotani , M.D., ... Programs.  In this role, Chotani will lead chemical and biological programs that ... of the Secretary of Defense, as well as civilian agencies such as ... Disease Control. , , , ...
... 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... results for the three and six months ended June 30, 2010 and reviewed the ... , The Company ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:7/9/2014)... to switch out one gene for another in a ... science fiction to reality within this decade. As with ... hope of fixing disease-causing genes in humans, for example--as ... have put one of those concerns to rest: using ... occurrence of mutations in the cells. The new results ...
(Date:7/9/2014)... LAFAYETTE, Ind. - Regulated deer hunts in Indiana state ... from decades of damage caused by overabundant populations of ... team led by Michael Jenkins, associate professor of forest ... Resources policy of organizing hunts in state parks has ... and wildflowers rendered scarce by browsing deer. , ...
(Date:7/9/2014)... from the Spanish National Cancer Research Centre (CNIO) have ... cells, also regulates cell division in stratified epitheliathose that ... cover the oesophagus or the vaginain adult organisms. According ... journal Nature Communications , this factor could also ... from stratified epithelia of the oesophagus and skin. , ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... serendipity, researchers at North Carolina State University have found ... of intestinal birth defects may also inhibit the growth ... of chemical compounds created by NC State chemist Dr. ... of particular interest to her research: a compound that ...
... Indonesia has promised to become a world leader ... committed to a 26% reduction in greenhouse gas emissions ... 14% would have to come from reducing emissions from ... and other bodies are expected to raise total emission ...
... global framework for the safe production and use of ... Australia. The South-Pacific plant has been traditionally used ... some countries. Leading world Kava experts Dr Jerome ... Teschke from Wolfgang Goethe-University, Frankfurt, Germany; and Dr Vincent ...
Cached Biology News:Compound useful for studying birth defects may also have anti-tumor properties 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 3Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 4Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 5Experts propose global guidelines for safe use of Kava and new Australian study 2
TUP1 Market Segment: Molecular Biology...
In plasmid or lambda vector. Please inquire for more details!...
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
... polyclonal to SARA ( Abpromise for ... Synthetic peptide: PVPKEMEQPV QTEEEDVELP conjugated to ... Fruit fly (Drosophila melanogaster) SARA. Conserved ... Entrez Gene ID: 9372 ...
Biology Products: